Logo image of OYST

OYSTER POINT PHARMA INC (OYST) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OYST - US69242L1061 - Common Stock

11.17 USD
+0.02 (+0.18%)
Last: 12/30/2022, 8:00:02 PM
11.17 USD
0 (0%)
After Hours: 12/30/2022, 8:00:02 PM
Fundamental Rating

1

Overall OYST gets a fundamental rating of 1 out of 10. We evaluated OYST against 530 industry peers in the Biotechnology industry. OYST has a bad profitability rating. Also its financial health evaluation is rather negative. OYST does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OYST has reported negative net income.
In the past year OYST has reported a negative cash flow from operations.
OYST Yearly Net Income VS EBIT VS OCF VS FCFOYST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

OYST has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OYST Yearly ROA, ROE, ROICOYST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OYST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OYST Yearly Profit, Operating, Gross MarginsOYST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

OYST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OYST has been increased compared to 1 year ago.
Compared to 1 year ago, OYST has a worse debt to assets ratio.
OYST Yearly Shares OutstandingOYST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
OYST Yearly Total Debt VS Total AssetsOYST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

OYST has an Altman-Z score of -7.49. This is a bad value and indicates that OYST is not financially healthy and even has some risk of bankruptcy.
OYST has a worse Altman-Z score (-7.49) than 76.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.49
ROIC/WACCN/A
WACC9.28%
OYST Yearly LT Debt VS Equity VS FCFOYST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

OYST has a Current Ratio of 3.35. This indicates that OYST is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of OYST (3.35) is worse than 69.57% of its industry peers.
A Quick Ratio of 3.11 indicates that OYST has no problem at all paying its short term obligations.
OYST's Quick ratio of 3.11 is on the low side compared to the rest of the industry. OYST is outperformed by 70.96% of its industry peers.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.11
OYST Yearly Current Assets VS Current LiabilitesOYST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

OYST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -113.14%.
The Revenue has grown by 9.15% in the past year. This is quite good.
EPS 1Y (TTM)-113.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
Revenue 1Y (TTM)9.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.84%

3.2 Future

OYST is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.70% yearly.
OYST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 105.78% yearly.
EPS Next Y-66.47%
EPS Next 2Y4.31%
EPS Next 3Y14.43%
EPS Next 5Y-0.7%
Revenue Next Year55.43%
Revenue Next 2Y130.27%
Revenue Next 3Y117.27%
Revenue Next 5Y105.78%

3.3 Evolution

OYST Yearly Revenue VS EstimatesOYST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 200M 400M 600M
OYST Yearly EPS VS EstimatesOYST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OYST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OYST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OYST Price Earnings VS Forward Price EarningsOYST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OYST Per share dataOYST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as OYST's earnings are expected to grow with 14.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.31%
EPS Next 3Y14.43%

More info and screens

0

5. Dividend

5.1 Amount

OYST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OYSTER POINT PHARMA INC

NASDAQ:OYST (12/30/2022, 8:00:02 PM)

After market: 11.17 0 (0%)

11.17

+0.02 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2022-11-10/amc
Earnings (Next)02-22 2023-02-22
Inst Owners0%
Inst Owner Change0%
Ins Owners31.31%
Ins Owner Change0%
Market Cap299.85M
Revenue(TTM)19.58M
Net Income(TTM)-176.65M
Analysts78
Price Target28.05 (151.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.77%
Min EPS beat(2)-10.44%
Max EPS beat(2)11.98%
EPS beat(4)1
Avg EPS beat(4)-3.32%
Min EPS beat(4)-13.56%
Max EPS beat(4)11.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.2%
Min Revenue beat(2)-20.89%
Max Revenue beat(2)-5.52%
Revenue beat(4)2
Avg Revenue beat(4)518.44%
Min Revenue beat(4)-20.89%
Max Revenue beat(4)2055.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.77%
PT rev (3m)N/A
EPS NQ rev (1m)0.9%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.16%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-8.11%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.96%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.31
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.65
EYN/A
EPS(NY)-3.53
Fwd EYN/A
FCF(TTM)-6.2
FCFYN/A
OCF(TTM)-6.18
OCFYN/A
SpS0.73
BVpS-0.83
TBVpS-0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 140.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.35
Quick Ratio 3.11
Altman-Z -7.49
F-Score2
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)976.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-113.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
EPS Next Y-66.47%
EPS Next 2Y4.31%
EPS Next 3Y14.43%
EPS Next 5Y-0.7%
Revenue 1Y (TTM)9.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.84%
Revenue Next Year55.43%
Revenue Next 2Y130.27%
Revenue Next 3Y117.27%
Revenue Next 5Y105.78%
EBIT growth 1Y-98.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.36%
EBIT Next 3Y-9.7%
EBIT Next 5Y-2.78%
FCF growth 1Y-206.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-208%
OCF growth 3YN/A
OCF growth 5YN/A

OYSTER POINT PHARMA INC / OYST FAQ

What is the ChartMill fundamental rating of OYSTER POINT PHARMA INC (OYST) stock?

ChartMill assigns a fundamental rating of 1 / 10 to OYST.


Can you provide the valuation status for OYSTER POINT PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to OYSTER POINT PHARMA INC (OYST). This can be considered as Overvalued.


How profitable is OYSTER POINT PHARMA INC (OYST) stock?

OYSTER POINT PHARMA INC (OYST) has a profitability rating of 0 / 10.


Can you provide the financial health for OYST stock?

The financial health rating of OYSTER POINT PHARMA INC (OYST) is 2 / 10.